The following Evaluation reports have been archived and are no longer available as downloads from this website. If you would like to have access to any of the documents listed please contact nuth.nyrdtc.rxsupp@nhs.net.
<< Return to the list of current Evaluation Reports
| Document | Published |
|---|---|
| Abiraterone for the treatment of castration-resistant prostate cancer | Feb 11 |
| ActiPatch | Jan 19 |
| Adacolumn in Inflammatory Bowel Disease (NETAG appraisal) | Jan 11 |
| Adefovir dipivoxil in chronic hepatitis B infection (N) | Jun 04 |
| Aflibercept for age-related macular degeneration (NETAG Appraisal) | Mar 12 |
| Alemtuzumab in chronic lymphocytic leukaemia | Mar 07 |
| An update on newer agents for the treatment of pulmonary hypertension | Mar 04 |
| Aprepitant for the prevention of chemotherapy induced nausea and vomiting | Mar 09 |
| Aromatase inhibitors in early stage breast cancer (N) | Mar 07 |
| Azacitidine for the management of myelodysplastic syndromes (N) | May 09 |
| Belimumab for the treatment of Systemic Lupus Erythematosus (SLE) | Apr 12 |
| Bendamustine for rituximab-refractory non-hodgkin’s lymphoma | Feb 11 |
| Bevacizumab in metastatic breast cancer (N) | Sep 07 |
| Birch bark extract (Episalvan) for the treatment of partial thickness wounds in adults | Sep 16 |
| Bortezomib second-line in multiple myeloma (N) | Mar 06 |
| Botox for chronic migraine (NETAG appraisal) | Sep 11 |
| Cabazitaxel for the treatment of metastatic hormone-refractory prostate cancer | Feb 11 |
| Dasatinib in the management of acute lymphoblastic leukaemia in adults | Aug 08 |
| Docetaxel or paclitaxel in early stage breast cancer (N) | Mar 06 |
| Doxylamine and pyridoxine (Xonvea®) for the treatment of nausea and vomiting of pregnancy |
Feb 19 |
| Drotrecogin alfa (activated) in severe sepsis (N) | Dec 02 |
| Eculizumab in atypical Haemolytic Uraemic Syndrome | Jul 12 |
| Entecavir in chronic hepatitis B (N) | Apr 07 |
| Erlotinib in non-small cell lung cancer | Mar 06 |
| Fampridine for the improvement of walking ability in multiple sclerosis | Sep 11 |
| Fulvestrant | Jan 18 |
| Human Immunodeficiency Virus (HIV) infection - new treatments | May 10 |
| Ibandronic acid in hypercalcaemia of malignancy, bone pain and the prevention of skeletal events associated with skeletal metastases | Aug 05 |
| Ibritumomab as consolidation therapy after remission induction in previously untreated follicular lymphoma | May 09 |
| Ibritumomab in b-cell follicular non-hodgkin’s lymphoma | Mar 06 |
| Insulin degludec in Diabetes mellitus | Aug 12 |
| Lapatinib in the management of metastatic breast cancer | Nov 08 |
| Myocet in the management of metastatic breast cancer | Aug 08 |
| Naloxone Nasal Spray | Sep 18 |
| Nanoparticle albumin-bound paclitaxel in the management of metastatic breast cancer | May 10 |
| Natalizumab in multiple sclerosis (N) | Mar 07 |
| Neuromodulatory drugs for cough | Nov 17 |
| Newer Topical Therapies for Actinic Keratoses | Apr 13 |
| Omalizumab in severe persistent allergic asthma (N) | Jun 06 |
| Ozurdex dexamethasone ocular implant for uveitis (NETAG appraisal) | Jan 12 |
| Palonosetron for the prevention of nausea and vomiting associated with cancer chemotherapy | Mar 07 |
| Panitumumab in the management of metastatic colorectal cancer (N) | Jun 06 |
| Pasireotide for Cushing’s disease (NETAG Appraisal) | Jun 12 |
| Pegvisomant in acromegaly | Jan 06 |
| Pemetrexed in malignant pleural mesothelioma (N) | Mar 06 |
| Perampanel for epilepsy (NETAG appraisal) | Oct 12 |
| Protease Inhibitors (Boceprevir & Telaprevir) in the treatment of Hepatitis C | Dec 11 |
| Pulmonary arterial hypertension - Current therapeutic strategies | Mar 09 |
| Rituximab in combination with cvp chemotherapy for the management of follicular non-hodgkin’s lymphoma | Mar 06 |
| Rituximab in rheumatoid arthritis: non-NICE approved indications (N) (NETAG APPRAISAL) |
Jul 11 |
| Roflumilast for COPD (NETAG appraisal) (N) | Jun 10 |
| Ruxolitinib for myelofibrosis | Jan 13 |
| Sativex for spasticity due to MS (NETAG appraisal) | Oct 10 |
| Sorafenib for the treatment of locally advanced or metastatic medullary thyroid cancer | Feb 11 |
| Sufentanil Sublingual Tablet for Post-Operative Pain | Mar 16 |
| Sunitinib for the treatment of Pancreatic Neuroendocrine Tumours (PNETs) | Mar 11 |
| Tapentadol for chronic pain | Jan 15 |
| Targinact for chronic pain | Jan 15 |
| Teriparatide in osteoporosis (N) | Jul 04 |
| Tocilizumab for juvenile idiopathic arthritis (NETAG appraisal) (N) | Jul 10 |
| Tolvaptan for SIADH (NETAG appraisal) | Apr 11 |
| Topical gabapentin | Nov 15 |
| Tumour Necrosis Factor Inhibitors for Rheumatoid Arthritis | May 13 |
| Vandetanib in locally advanced or metastatic medullary thyroid cancer | Feb 11 |
